I cannot seem to make sense of the indications that are approved for particular drugs (cancer drugs in particular). It seems you now define “approved indication” when an indication is listed for the drug in a clinical trial with a maximum phase of IV. I reckoned this is the strategy, since this is in line with what is stated at the top Description paragraph of the Profile tab for a given drug.
A couple of examples that shows the lack of approved indications:
Olaparib - a well-known PARP inhibitor is now approved for multiple tumor types. According to data from the Open Targets Platform, only ovarian cancer seems to be the approved (tumor-type specific) indication.
Unless I am interpreting the indication data in in unintended manner, I think these aspects are fairly important elements to improve/rectify in future releases.
Thanks again for a great resource,